Effect of atrial antitachycardia pacing treatments in patients with an atrial defibrillator: randomised study comparing subthreshold and nominal pacing outputs

A R J Mitchell, P A R Spurrell, L Cheatle, N Sulke

Methods

Patients
A Medtronic Jewel AF® atrial defibrillator was implanted in 15 patients, the sole indication being drug refractory persistent atrial fibrillation. The participants were 12 men and three women (mean age 63.0 years, range 38 to 83). None of them had a history of ventricular arrhythmia or any documented evidence of paroxysmal atrial fibrillation on repeated preimplant 24 hour Holter monitoring and careful review of the clinical records. All patients underwent cardioversion to sinus rhythm during implantation as part of the device testing procedure.

Effects of 50 Hz atrial pacing on induced atrial fibrillation
At predischarge testing, atrial fibrillation was induced in all patients by a two second burst of 50 Hz atrial pacing at an amplitude of 8 V and a pulse width of 1.5 ms. Atrial fibrillation was allowed to stabilise for two minutes. A two second burst of 50 Hz atrial pacing was then delivered in an attempt to terminate the rhythm. If atrial fibrillation persisted, then the rhythm was finally cardioverted by patient activated defibrillation using the Jewel AF® and a remote activator (Medtronic model 9464).

Effects of atrial pacing treatments on spontaneous atrial episodes
All patients were studied six months after implantation of the atrial defibrillator. Each patient was randomised to three month periods of atrial treatments, with outputs set at either “nominal” (5 V output and 1.5 ms pulse width) or proven subthreshold “sham” pacing (1 V output and 0.03 ms pulse width). Atrial pacing was performed at sham outputs before final programming to confirm that there was no atrial capture on either the surface ECG or the endocardial electrogram. Atrial pacing treatment was initiated after two minutes of a recognised atrial arrhythmia. After three months, the patients

The management of paroxysmal and persistent atrial fibrillation has changed over the last decade, with a gradual move away from reliance on medical treatment alone. Hybrid treatments involving various electrophysiological and pacing techniques are now being used in synergy with conventional pharmaceutical treatment. Newer and more sophisticated pacemaker technologies are being investigated and efforts focused on finding methods of either terminating atrial fibrillation early or reducing the burden of arrhythmia.1

The Medtronic (Minneapolis, USA) Jewel AF® defibrillator (model 7250) allows tiered atrial treatment to be delivered on detection of atrial arrhythmias. Stored Holter and endocardial electrogram strip recordings allow the precise onset and termination of atrial arrhythmias to be determined and the effects of treatment assessed. The patients who seem to benefit particularly from the atrial defibrillator are those in whom the only arrhythmia is recurrent drug resistant persistent atrial fibrillation.2 Previous studies investigating the effects of atrial pacing treatment using the Jewel AF® have, however, also included patients with paroxysmal atrial fibrillation and ventricular arrhythmias.2 4

Our aims were to investigate atrial pacing treatment in patients with persistent atrial fibrillation only, as follows: (1) to show the effects of atrial pacing at either nominal or subthreshold “sham” outputs on spontaneous persistent atrial fibrillation, using a randomised crossover design; (2) to investigate the efficacy of 50 Hz atrial pacing for terminating induced and spontaneous persistent atrial fibrillation.

Methods

Patients
A Medtronic Jewel AF® atrial defibrillator was implanted in 15 patients, the sole indication being drug refractory persistent atrial fibrillation. The participants were 12 men and three women (mean age 63.0 years, range 38 to 83). None of them had a history of ventricular arrhythmia or any documented evidence of paroxysmal atrial fibrillation on repeated preimplant 24 hour Holter monitoring and careful review of the clinical records. All patients underwent cardioversion to sinus rhythm during implantation as part of the device testing procedure.

Effects of 50 Hz atrial pacing on induced atrial fibrillation
At predischarge testing, atrial fibrillation was induced in all patients by a two second burst of 50 Hz atrial pacing at an amplitude of 8 V and a pulse width of 1.5 ms. Atrial fibrillation was allowed to stabilise for two minutes. A two second burst of 50 Hz atrial pacing was then delivered in an attempt to terminate the rhythm. If atrial fibrillation persisted, then the rhythm was finally cardioverted by patient activated defibrillation using the Jewel AF® and a remote activator (Medtronic model 9464).

Effects of atrial pacing treatments on spontaneous atrial episodes
All patients were studied six months after implantation of the atrial defibrillator. Each patient was randomised to three month periods of atrial treatments, with outputs set at either “nominal” (5 V output and 1.5 ms pulse width) or proven subthreshold “sham” pacing (1 V output and 0.03 ms pulse width). Atrial pacing was performed at sham outputs before final programming to confirm that there was no atrial capture on either the surface ECG or the endocardial electrogram. Atrial pacing treatment was initiated after two minutes of a recognised atrial arrhythmia. After three months, the patients
were crossed over to the alternative treatment. Drug treatment remained unchanged for the duration of the study.

**Arrhythmia classification**

The device was programmed to classify an atrial arrhythmia as atrial fibrillation if the mean atrial cycle length was between 100 ms and 270 ms. Atrial tachycardia was diagnosed if the cycle length fell between 170 ms and 320 ms. Within the overlap zone, the Jewel AF® discriminated between atrial fibrillation and atrial tachycardia according the regularity of the rhythm (fig 1). The rhythm was classified as regular when, in the most recent 12 intervals, the difference between the shortest and the longest atrial interval was less than or equal to 25% of the atrial median interval. Antitachycardia pacing treatment was then delivered if the cycle length was regular for six of the preceding eight intervals. If the cycle length was not stable, antitachycardia pacing treatment was withheld and counters restarted. Some tachycardia episodes could therefore be temporarily classified as different rhythms if the arrhythmia accelerated or decelerated into different detection zones or became more or less regular.

The term “paroxysmal” was used to describe any spontaneously terminating episodes of arrhythmia, whereas “persistent” was used to describe all episodes that required patient activated cardioversion. Atrial tachycardia is used to describe all regular episodes of atrial arrhythmia (including atrial flutter).

**Delivered treatments**

Atrial treatments were delivered according to the initial episode rhythm classification by the Jewel AF® device, and again if the arrhythmia was reclassified during each episode. On classification as atrial fibrillation, the device can only deliver 50 Hz atrial pacing, and a second burst was programmed to be delivered. On classification as atrial tachycardia, the device delivered up to six sequences of atrial ramp pacing (ARamp), six sequences of atrial burst pacing (ABurst+), and a second burst of 50 Hz atrial pacing. After each delivered treatment the device looks for restoration of sinus rhythm before proceeding with the next treatment sequence (table 1). Atrial fibrillation could only receive ARamp or ABurst+ treatments if the rhythm was temporarily reclassified as atrial tachycardia by the device.

**Atrial pacing treatment**

50 Hz pacing—A two second burst of rapid atrial pacing with pacing interval of 20 ms.

Atrial ramp pacing (ARamp)—Six pulses of AOO pacing with the first stimulus of each sequence delivered at 94% of the preceding atrial cycle length (table 1). The remainder of the sequence was delivered at progressively shorter intervals with a programmed interval decrement of 10 ms. Each time the tachycardia was redetected the sequence was delivered at 94% of the redetected cycle length and an extra stimulus was added to the sequence.

Atrial burst pacing (ABurst+)—10 pulses of AOO pacing at 94% of the atrial cycle length. This was followed by an extra stimulus at 91% of the cycle length and a further stimulus 10 ms shorter than 91% of the cycle length. Each time the tachycardia was redetected, the programmed intervals were reapplied with a 10 ms decrement to the new arrhythmia cycle length.

**Definition of successful termination**

Successful termination was defined as the restoration of atrioventricular synchrony for at least one beat within five atrial beats of the last stimulus of pacing treatment, even if early recurrence of the arrhythmia occurred thereafter. The Jewel AF® device, however, defines successful termination when it detects five consecutive beats of sinus rhythm within three minutes of treatment delivery. To assess the number of episodes that spontaneously terminated after pacing treatments were delivered and were therefore classified as successfully terminated by the Jewel AF®, we examined endocardial electrograms of all episodes terminating within one minute of delivery of pacing treatment.

**Follow up**

Patients were reviewed at the end of each three month study phase, the device was interrogated using a conventional programmer, and all data were downloaded to disc. Atrial electrograms were studied and compared with the device classification of each episode. The median atrial cycle length (at the electrode tip) of each arrhythmia was recorded for each episode. After completion of the study period, atrial pacing treatments were reprogrammed at the clinician’s discretion.

**Statistics**

Values are given as mean (SD). Atrial cycle lengths were grouped according to rhythm classification and averages and variance calculated. Comparisons of atrial cycle lengths was by Student’s t test. A probability (p) value of < 0.05 indicated statistical significance.

**RESULTS**

**Spontaneous atrial episodes**

Mean follow up periods were 93.4 days with nominal output and 92.7 days with sham output. Sixty two atrial episodes occurred during the nominal period and 67 during the sham phase. Episodes were classified according to interpretation of stored atrial electrograms. There were 57 episodes of atrial fibrillation, with 11 spontaneously terminating episodes. The mean cycle length of persistent atrial fibrillation was 199 (38) ms, and of paroxysmal atrial fibrillation, 238 (36) ms (p < 0.005). There were 72 episodes of atrial tachycardia, with

---

**Table 1 Atrial pacing treatments**

<table>
<thead>
<tr>
<th>AF treatments</th>
<th>AT treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pacing (50 Hz)</td>
<td>1. Pacing (ARamp)</td>
</tr>
<tr>
<td>One burst, duration 2 s</td>
<td>Six bursts</td>
</tr>
<tr>
<td></td>
<td>Six pulses</td>
</tr>
<tr>
<td></td>
<td>12 Pulses</td>
</tr>
<tr>
<td></td>
<td>A–S1 interval 94% of AA</td>
</tr>
<tr>
<td></td>
<td>Interval deceleration 10 ms</td>
</tr>
<tr>
<td>2. Pacing (ABurst+)</td>
<td>Six bursts</td>
</tr>
<tr>
<td></td>
<td>12 Pulses</td>
</tr>
<tr>
<td></td>
<td>A–S1 interval 94% of AA</td>
</tr>
<tr>
<td></td>
<td>S1–S2 interval 91% of AA</td>
</tr>
<tr>
<td></td>
<td>S2–S3 decrement 20 ms</td>
</tr>
<tr>
<td></td>
<td>Interval deceleration 10 ms</td>
</tr>
<tr>
<td>3. Pacing (50 Hz)</td>
<td>One burst, duration 2 s</td>
</tr>
</tbody>
</table>

For atrial fibrillation (AF), only 50 Hz atrial pacing can be programmed. Tiered atrial treatment can be programmed for atrial tachycardia (AT) with ramp, burst+, and 50 Hz pacing. Ramp and burst+ treatments can therefore only be delivered in AF if the device misclassifies the rhythms as AT.
The device initially classified arrhythmic episodes as atrial fibrillation in 42 cases and atrial tachycardia in 15 cases. Of these latter 15 episodes, 11 were subsequently reclassified by the device as atrial fibrillation. Overall, 49 of the 57 episodes of atrial fibrillation were temporarily classified as atrial tachycardia and atrial tachycardia treatments were given.

The effect of antitachycardia pacing treatment
Delivered treatments are documented in table 3. “ARamp” treatments were delivered during 58 atrial episodes when programmed to nominal output with 201 sequences of pacing treatment. During the sham period, 63 episodes received 292 sequences of treatment. “ARamp” antitachycardia pacing failed to terminate a single case of atrial fibrillation; however, it successfully terminated 16 episodes of atrial tachycardia in one patient (mean of two sequences of treatment). “Burst+” pacing was delivered 99 times during 25 episodes with nominal outputs, and 204 times in 36 episodes when programmed to nominal and 26 to sham treatments. All these episodes were atrial tachycardia.

The effect of 50 Hz atrial pacing
Atrial fibrillation
Thirty one episodes of atrial fibrillation were treated with 50 Hz pacing in the laboratory setting. They showed that during induced atrial fibrillation in the dog it was possible to capture small regions of atrial tissue by rapid pacing, particularly when pacing the left atrium. They found that pacing with a cycle length slightly shorter than the mean fibrillation interval led to the penetration of paced wavefronts into the excitable gap. Daoud et al similarly demonstrated regional capture during pacing induced atrial fibrillation, with acceleration and increased disorganisation in distant atrial electrograms, but failed to terminate the rhythm.

Atrial flutter, on the other hand, is well known to be amenable to pace termination. In 1977, Waldo et al showed entrainment and pace termination of atrial flutter. Termination of atrial fibrillation is more difficult owing to the inhomogeneity of the atrial tissue, the numbers and variable size of separate wandering wavelets, and the smaller excitable gap. In addition, when Allessie and coworkers found that during induced atrial fibrillation in the dog it was possible to capture small regions of atrial tissue by rapid pacing, particularly when pacing the left atrium. They found that pacing with a cycle length slightly shorter than the mean fibrillation interval led to the penetration of paced wavefronts into the excitable gap. Daoud et al similarly demonstrated regional capture during pacing induced atrial fibrillation, with acceleration and increased disorganisation in distant atrial electrograms, but failed to terminate the rhythm.

A significant proportion of cases of atrial fibrillation may start with atrial flutter or atrial tachycardia and degenerate into atrial fibrillation. This allows a window of opportunity to pace-terminate such arrhythmias. Previous studies of the

### Table 2 Arrhythmia episode frequency, distribution, and mean atrial cycle length (ACL)

<table>
<thead>
<tr>
<th></th>
<th>No of episodes</th>
<th>No of patients</th>
<th>Mean ACL (ms)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persistent AF</td>
<td>46</td>
<td>10</td>
<td>199 (38)</td>
</tr>
<tr>
<td>Paroxysmal AF</td>
<td>11</td>
<td>3</td>
<td>238 (36)</td>
</tr>
<tr>
<td>Persistent AT</td>
<td>6</td>
<td>2</td>
<td>217 (36)</td>
</tr>
<tr>
<td>Paroxysmal AT</td>
<td>49</td>
<td>4</td>
<td>228 (32)</td>
</tr>
<tr>
<td>Terminated AT</td>
<td>17</td>
<td>1</td>
<td>234 (33)</td>
</tr>
</tbody>
</table>

Values are mean (SD).

AF, atrial fibrillation; AT, atrial tachycardia.

Table 3 Number of atrial treatments delivered with pacemaker outputs programmed to nominal or sham

<table>
<thead>
<tr>
<th></th>
<th>AF treatment 1: AF 50 Hz</th>
<th>AT treatment 1: ARamp</th>
<th>No of sequences</th>
<th>AT treatment 2: ABurst+</th>
<th>No of sequences</th>
<th>AT treatment 3: 50 Hz</th>
<th>No of sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nominal AF</td>
<td>31</td>
<td>31</td>
<td>29</td>
<td>98</td>
<td>17</td>
<td>61</td>
<td>22</td>
</tr>
<tr>
<td>Flutter</td>
<td>31</td>
<td>13</td>
<td>29</td>
<td>103</td>
<td>8</td>
<td>38</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>62</td>
<td>44</td>
<td>58</td>
<td>201</td>
<td>25</td>
<td>99</td>
<td>26</td>
</tr>
<tr>
<td>Sham AF</td>
<td>26</td>
<td>26</td>
<td>22</td>
<td>108</td>
<td>15</td>
<td>87</td>
<td>21</td>
</tr>
<tr>
<td>Subthreshold</td>
<td>41</td>
<td>13</td>
<td>41</td>
<td>184</td>
<td>21</td>
<td>117</td>
<td>20</td>
</tr>
<tr>
<td>Total</td>
<td>67</td>
<td>37</td>
<td>63</td>
<td>292</td>
<td>36</td>
<td>204</td>
<td>41</td>
</tr>
</tbody>
</table>

AF, atrial fibrillation; AT, atrial tachycardia.
This highlights the problem of defining successful termination. We have used an immediate restoration of sinus rhythm to define success, although it is clear from our data that if we had used longer time periods after pacing treatments then we would have had different results. Termination within 30 seconds to one minute after treatment may be a chance finding, but if termination occurs within a few seconds of treatment it is likely to be a therapeutic effect. Twenty seven of 129 episodes were incorrectly classified as “successfully terminated” by the device in this study, although none of those episodes was atrial fibrillation and they were mostly confined to one patient. Each episode’s electrogram and marker traces were critically reviewed before success was defined in our study. Many studies investigating device treatment for termination of atrial fibrillation need to be interpreted with caution when using device defined criteria alone.

High frequency (50 Hz) burst atrial pacing is often used to initiate atrial fibrillation during electrophysiological studies, and for testing atrial defibrillators. The failure of 50 Hz burst pacing to terminate atrial fibrillation in this study is in keeping with several studies of induced atrial fibrillation in man. Paladino and coworkers induced atrial fibrillation in 28 patients and attempted high frequency pacing from single and multiple sites, with no terminations. Similar work with varying burst durations of 50 Hz atrial pacing revealed termination in six of 10 patients with atypical atrial flutter but no success in any patients with atrial fibrillation.

Our study investigated the effects of atrial treatments in a specific group of patients with persistent atrial fibrillation only. There was no previous history of spontaneously terminating episodes in spite of multiple Holter tests, and no history of ventricular arrhythmias. However, four patients had self terminating episodes of atrial fibrillation or atrial tachycardia during the study period. In one of these patients and during nominal outputs, 17 of 25 episodes of atrial tachycardia were pace terminated by ramp atrial pacing. It seems that the early termination of these episodes did not result in a reduced requirement for defibrillation, because in the same patient all atrial tachycardia episodes terminated spontaneously during the sham phase of the study, without requiring defibrillation.

**Study limitations**

The main aim of our study was to investigate the effects of pacing treatments on spontaneous persistent atrial fibrillation. We allowed a two minute period for the rhythm to stabilise before starting pacing treatment, to ensure that there was no early spontaneous termination. It may be that during that period some arrhythmia episodes are more amenable to pace termination. Similarly, some episodes of persistent atrial fibrillation were terminated by the device, but if termination occurs within a few seconds of treatment it is likely to be a therapeutic effect. Twenty seven of 129 episodes were incorrectly classified as “successfully terminated” by the device in this study, although none of those episodes was atrial fibrillation and they were mostly confined to one patient. Each episode’s electrogram and marker traces were critically reviewed before success was defined in our study. Many studies investigating device treatment for termination of atrial fibrillation need to be interpreted with caution when using device defined criteria alone.
Atrial antitachycardia pacing

Magnetic resonance angiography showing bilateral subclavian artery aneurysm and stenosis in Marfan’s syndrome

A 26 year old woman with Marfan’s syndrome presented with right sided neck discomfort and buzzing, but without neurological symptoms. A pulsatile swelling was palpable above the right clavicle.

The patient had previously had a dissecting aneurysm of the ascending aorta at the age of 13 years, for which her aortic valve and ascending aorta had been replaced with a Bjork-Shiley prosthetic valve and Dacron graft. At the age of 19 she had graft replacement of her descending thoracic aorta, distal to the left subclavian artery, for a further dissecting aneurysm.

Gadolinium enhanced magnetic resonance angiography showed localised fusiform aneurysms, maximum diameter 23 mm, close to the origins of both right and left subclavian arteries (right). There was also evidence of stenosis of both right and left subclavian arteries distal to each aneurysm, the left sided stenosis being more severe than that on the right. Both vertebral arteries originated from the aneurysmal subclavian artery segments. No dissection of the aortic arch or its branches was seen.

This unusual pattern of arteriopathy, apparently associated with Marfan’s disease, with almost symmetric dilatation and stenosis of both subclavian arteries, has not, as far as we know, been reported previously.

B Sievers
P Kilner
R Mohiaddin
r.mohiaddin@rbh.nthames.nhs.uk

REFERENCES


Effect of atrial antitachycardia pacing treatments in patients with an atrial defibrillator: randomised study comparing subthreshold and nominal pacing outputs

A R J Mitchell, P A R Spurrell, L Cheatle and N Sulke

*Heart* 2002 87: 433-437
doi: 10.1136/heart.87.5.433

Updated information and services can be found at:
http://heart.bmj.com/content/87/5/433

These include:

References
This article cites 16 articles, 6 of which you can access for free at:
http://heart.bmj.com/content/87/5/433#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Tachyarrhythmias (208)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/